SG11202009262VA - Salts of compounds and crystals thereof - Google Patents
Salts of compounds and crystals thereofInfo
- Publication number
- SG11202009262VA SG11202009262VA SG11202009262VA SG11202009262VA SG11202009262VA SG 11202009262V A SG11202009262V A SG 11202009262VA SG 11202009262V A SG11202009262V A SG 11202009262VA SG 11202009262V A SG11202009262V A SG 11202009262VA SG 11202009262V A SG11202009262V A SG 11202009262VA
- Authority
- SG
- Singapore
- Prior art keywords
- crystals
- salts
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000013078 crystal Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6587—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having two phosphorus atoms as ring hetero atoms in the same ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862764774P | 2018-08-16 | 2018-08-16 | |
PCT/JP2019/031951 WO2020036199A1 (en) | 2018-08-16 | 2019-08-14 | Salts of compounds and crystals thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009262VA true SG11202009262VA (en) | 2020-10-29 |
Family
ID=69525441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009262VA SG11202009262VA (en) | 2018-08-16 | 2019-08-14 | Salts of compounds and crystals thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US11691990B2 (zh) |
EP (1) | EP3837268A4 (zh) |
JP (1) | JP6767589B1 (zh) |
KR (1) | KR20210045352A (zh) |
CN (1) | CN112041325B (zh) |
AU (1) | AU2019322722A1 (zh) |
BR (1) | BR112021001349A2 (zh) |
CA (1) | CA3099904A1 (zh) |
MX (1) | MX2020013322A (zh) |
SG (1) | SG11202009262VA (zh) |
TW (1) | TWI717804B (zh) |
WO (1) | WO2020036199A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220111028A1 (en) | 2020-10-14 | 2022-04-14 | Boehringer Ingelheim International Gmbh | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
EP1729781B1 (en) | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
CN102199183B (zh) | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
SG11201407875UA (en) | 2012-06-08 | 2014-12-30 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
HUE043262T2 (hu) | 2012-12-13 | 2019-08-28 | Aduro Biotech Inc | Meghatározott sztereokémiájú ciklikus purindinukleotidokat tartalmazó készítmények, valamint eljárások elõállításukra és alkalmazásukra |
EP2934598B1 (en) * | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
PE20160167A1 (es) * | 2013-04-29 | 2016-04-21 | Sloan Kettering Inst Cancer | Composiciones y metodos para alterar la senalizacion del segundo mensajero |
CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
SG11201508273RA (en) | 2013-05-18 | 2015-12-30 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
WO2016079899A1 (ja) | 2014-11-20 | 2016-05-26 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 異なる核酸アジュバントの組み合わせによる、新規Th1誘導性アジュバントおよびその用途 |
ES2764178T3 (es) | 2014-12-16 | 2020-06-02 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para inducción de citocinas |
US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
CN107106589A (zh) | 2014-12-17 | 2017-08-29 | 立博美华基因科技有限责任公司 | 用cGAMP或cGAsMP治疗癌症的方法 |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
WO2017011622A1 (en) | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions that induce rig-i-and other pattern recongnition receptors |
EP3325473A4 (en) | 2015-07-22 | 2019-06-26 | The Royal Institution for the Advancement of Learning / McGill University | Compounds and uses thereof in the treatment of cancer and other medical disorders |
WO2017027645A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
US9809597B2 (en) | 2015-08-20 | 2017-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy |
CN108289912A (zh) | 2015-09-01 | 2018-07-17 | 先天肿瘤免疫公司 | 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途 |
TW201726700A (zh) | 2015-10-28 | 2017-08-01 | 艾杜諾生物科技公司 | 用於活化「干擾素基因刺激子」依賴性訊號之組合物及方法 |
EP3322713B1 (en) | 2015-12-03 | 2021-01-20 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
PE20181330A1 (es) | 2016-01-11 | 2018-08-20 | Innate Tumor Immunity Inc | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer |
EP3429596B1 (en) | 2016-03-18 | 2022-08-31 | Immune Sensor, LLC | Cyclic di-nucleotide compounds and methods of use |
SG11201808708RA (en) | 2016-04-07 | 2018-11-29 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
WO2018140831A2 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
US20200055883A1 (en) * | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
JP6909061B2 (ja) | 2017-06-13 | 2021-07-28 | 株式会社三共 | 遊技機 |
-
2019
- 2019-08-14 WO PCT/JP2019/031951 patent/WO2020036199A1/en unknown
- 2019-08-14 CA CA3099904A patent/CA3099904A1/en active Pending
- 2019-08-14 CN CN201980025277.0A patent/CN112041325B/zh active Active
- 2019-08-14 BR BR112021001349-0A patent/BR112021001349A2/pt not_active Application Discontinuation
- 2019-08-14 AU AU2019322722A patent/AU2019322722A1/en not_active Abandoned
- 2019-08-14 SG SG11202009262VA patent/SG11202009262VA/en unknown
- 2019-08-14 TW TW108128873A patent/TWI717804B/zh not_active IP Right Cessation
- 2019-08-14 JP JP2019565031A patent/JP6767589B1/ja active Active
- 2019-08-14 EP EP19850709.7A patent/EP3837268A4/en active Pending
- 2019-08-14 KR KR1020207030563A patent/KR20210045352A/ko not_active Application Discontinuation
- 2019-08-14 US US17/058,406 patent/US11691990B2/en active Active
- 2019-08-14 MX MX2020013322A patent/MX2020013322A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019322722A1 (en) | 2020-10-15 |
BR112021001349A2 (pt) | 2021-04-20 |
CN112041325B (zh) | 2023-10-24 |
EP3837268A4 (en) | 2022-04-20 |
EP3837268A1 (en) | 2021-06-23 |
KR20210045352A (ko) | 2021-04-26 |
MX2020013322A (es) | 2021-02-22 |
JP6767589B1 (ja) | 2020-10-14 |
US20210198282A1 (en) | 2021-07-01 |
CN112041325A (zh) | 2020-12-04 |
TW202015701A (zh) | 2020-05-01 |
WO2020036199A1 (en) | 2020-02-20 |
US11691990B2 (en) | 2023-07-04 |
TWI717804B (zh) | 2021-02-01 |
CA3099904A1 (en) | 2020-02-20 |
JP2020529967A (ja) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279468A (en) | Crystallographic modifications of odeviccibat | |
IL271028A (en) | Inhibition of crystal growth of roflumilest | |
IL279195A (en) | New salts and crystals | |
EP3436455A4 (en) | NOVEL SALTS AND CRYSTALS | |
IL288062A (en) | Crystalline forms of tapamidis and its salts | |
IL265730A (en) | Crystalline forms and salts of ppar agonist compounds | |
IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
IL283480A (en) | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof | |
IL282552A (en) | Crystalline forms of MNK inhibitors | |
IL266003A (en) | Salts of indazole derivatives and their crystals | |
IL281229A (en) | Salts of cycloserine compounds and their applications | |
SG11202106210QA (en) | Salt of syk inhibitor and crystalline form thereof | |
SG11202009262VA (en) | Salts of compounds and crystals thereof | |
ZA202101589B (en) | Crystal form of tri-cycle compound and application thereof | |
LT3424930T (lt) | Junginio, turinčio jak slopinantį aktyvumą, kristalas | |
IL274758A (en) | Crystalline forms of praquinostat | |
IL272835A (en) | Salts of a compound and crystalline forms thereof | |
ZA202007037B (en) | Crystal form of c-met inhibitor and salt form thereof and preparation method therefor | |
IL277578A (en) | New salt forms of URAT-1 inhibitors | |
HUE038041T2 (hu) | Fuzionált pirimidin vegyület új sója és annak kristálya | |
ZA201901155B (en) | Salt and crystal of diaza-benzofluorane compound | |
SG11202105355XA (en) | Crystalline salts of corydalmine | |
EP3889157C0 (en) | SALT AND CRYSTALLINE FORM OF A FUROPYRIMIDINE COMPOUND AND THEIR PHARMACEUTICAL USE | |
EP3845534A4 (en) | SALT FORM AND CRYSTALLINE FORM OF A NEW AZATRICYCLIC COMPOUND AND USE THEREOF | |
EP3849663C0 (en) | PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE |